MagPortal.com   Clustify - document clustering
 Home  |  Newsletter  |  My Articles  |  My Account  |  Help 
Similar Articles
The Motley Fool
December 30, 2003
Tom Taulli
M&A As Strong Medicine Invitrogen's latest deal shows that the company knows where its market is headed. mark for My Articles similar articles
The Motley Fool
February 7, 2008
Brian Orelli
A Lab Match Made in Heaven The case of Thermo Electron and Fisher Scientific shows why mergers work. mark for My Articles similar articles
Chemistry World
May 10, 2006
Katharine Sanderson
Leading Lab Suppliers Merge Analytical instrument firm Thermo Electron and chemical manufacturer Fisher Scientific announced a merger, aiming to become the leading provider of laboratory products and services in the health sciences industry. mark for My Articles similar articles
The Motley Fool
October 26, 2007
Brian Orelli
This Just In: Mergers Do Indeed Lower Costs As the anniversary integration between Thermo Electron and Fisher Scientific approaches next week, Thermo Fisher Scientific announced third-quarter results that demonstrated how the integration is having a nice effect on the bottom line. mark for My Articles similar articles
The Motley Fool
October 26, 2011
Tim Beyers
Thermo Fisher Scientific Shares Plunged: What You Need to Know Shares of Thermo Fisher Scientific fell more than 10% in early trading and closed off almost that much after lowering full-year earnings and revenue guidance. mark for My Articles similar articles
The Motley Fool
August 14, 2007
Brian Orelli
Drugmaker Growth Without the FDA Do you have one of those stomachs that just can't take the ups and downs of clinical trial data and FDA approval decisions? Buy stocks in the companies that support the drug makers. mark for My Articles similar articles
Bio-IT World
January 12, 2004
Kevin Davies
The Ultimate Platform Firm Greg Lucier on determinism in drug development at Invitrogen mark for My Articles similar articles
The Motley Fool
May 2, 2006
Ryan Fuhrmann
Sigma-Aldrich Surpasses Average Don't be fooled by appearances -- this isn't your typical chemical company. The shares have had a nice run over the past year, from about $55 to around $68.39. Even at current levels, the shares may be worth picking up, since they appear fairly valued. mark for My Articles similar articles
The Motley Fool
July 26, 2006
Ryan Fuhrmann
Sigma-Aldrich's Steady Growth Growth at this life science company is steady, not spectacular. With a current stock price of $67.78, the shares trade at about 17 times projected earnings. mark for My Articles similar articles
Bio-IT World
August 2005
Maureen McDonough
Invitrogen Launches iPath Invitrogen has unveiled a free bioinformatics and systems biology research tool that can be found on the company's Web site. iPath allows users to click their way through 2,500 human genes, 171 signal transduction pathways, and 54 metabolic pathways. mark for My Articles similar articles
The Motley Fool
October 7, 2010
DRIP Portfolio Candidate: Becton, Dickinson Profit from your fear of needles by adding this stock to your DRIP portfolio. mark for My Articles similar articles
The Motley Fool
October 21, 2010
Moser & Hinmon
DRIP Candidate Winner: Becton, Dickinson In a health-care bloodbath, Becton, Dickinson pounds Walgreen to a pulp. mark for My Articles similar articles